Women’s Health Clinic FAQ
How effective is MonaLisa or NuV from The Womens Health Clinic Touch laser for vaginal atrophy?
This question matters because laser is often marketed with more certainty than the evidence can justify. Women who cannot use or do not want vaginal oestrogen understandably want to know whether laser is a credible alternative. It can be discussed as an option, but not as if the uncertainty has already been settled.
Direct answer
Some studies and specialist guidance suggest that vaginal laser treatment can improve dryness, dyspareunia and other GSM symptoms in selected women, especially over the short term. But the strongest current UK message is caution: NICE says transvaginal laser therapy for urogenital atrophy should only be done as part of a research study because there is not enough evidence to be sure how well it works or how safe it is. So the honest answer is that it may help some women, but it is not established first-line care and the evidence is still incomplete.
The safest frame is not “does it work, yes or no?” but “what level of evidence do we actually have, and how should that change expectations?” You can book a confidential consultation if you want a structured review rather than continuing to guess the cause.
Educational only. Clinical suitability must be confirmed following an appropriate consultation and assessment by a qualified healthcare professional. Results vary. Not a cure.
At a glance
Think possible benefit, limited long-term evidence and a current UK research-only stance from NICE.
Diagnostic Differentiators
Key physical and clinical parameters
NICE status
Research only
Short-term data
Some improvement
Long-term certainty
Limited
Best for
Selected women only
Critical Progressive Risk
Educational only. Dryness can have hormonal, inflammatory, pelvic-floor, medication-related and sexual-health causes, so treatment should follow assessment rather than guesswork.
Why laser can sound more certain than it is
Laser is often described in confident marketing language, but UK guidance still treats the evidence base as incomplete.
Key Overlapping Symptom Triggers
That does not mean no woman improves. It means improvement reports need to be weighed against limited comparative and long-term data.
NICE says research study only
NICE states that transvaginal laser therapy should only be done as part of research because evidence on efficacy and safety is not yet strong enough.
RCOG describes promising but small studies
RCOG notes that published studies have shown promising results, but most have been small, short-term and observational.
BMS sees a potential role for selected women
BMS says laser may offer an option for women who cannot use hormonal therapy or struggle with adherence, while also emphasising the need for better evidence.
Expectation setting is essential
Any benefit needs to be discussed alongside uncertainty about durability, repeat treatments and long-term safety.
Most useful answer
Laser may improve GSM symptoms in some women, especially in short-term studies.
Current UK guidance is still cautious enough that NICE limits it to research settings rather than routine treatment.
Why this question needs a careful answer
Women seeking non-hormonal options deserve clarity, especially when commercial language can outrun the evidence.
There is real patient demand
Some women cannot use or do not want vaginal oestrogen, so non-hormonal alternatives matter.
Short-term symptom improvement is not the same as established routine care
Promising studies do not automatically resolve questions about long-term effectiveness or safety.
Repeat treatment may be needed
BMS notes that courses are typically repeated, which affects cost, expectations and convenience.
Guideline status matters clinically
A treatment restricted to research by NICE should not be presented as settled mainstream care.
Why the symptom pattern matters
Dryness is a symptom, not a full diagnosis. The right plan depends on cause, tissue quality, symptom severity, urinary symptoms, pain pattern and menopause status.
A good consultation aims to identify the cause early so that you do not spend months trying the wrong products or blaming yourself for symptoms that are medically treatable.
How to interpret “effective” in laser marketing
The most honest interpretation is that benefit is plausible and reported, but not yet proven strongly enough for routine unrestricted use.
Helpful benchmark
If a treatment sounds established in adverts but NICE still restricts it to research, that gap should directly shape expectations.
Ask about the evidence quality
Look for whether claims are based on small observational studies or stronger comparative trials.
Ask what counts as success
Improved dryness, dyspareunia or comfort are not the same as proven long-term tissue restoration.
Ask whether first-line options have been optimised
Mainstream care still prioritises local oestrogen, lubricants and moisturisers before laser.
Ask what happens if it does not help
A realistic plan includes follow-up, reassessment and alternatives rather than open-ended hope.
Practical takeaway
Laser can be discussed as a potentially helpful option, particularly for selected women who need alternatives.
It should be approached with evidence-aware caution, not marketed certainty.
Myths about laser effectiveness for vaginal atrophy
These myths usually come from mistaking early promise for settled clinical consensus.
Myth: Laser is now a proven mainstream replacement for vaginal oestrogen
False. NICE still restricts transvaginal laser therapy to research settings.
Myth: If studies show improvement, the long-term questions are solved
False. Short-term symptom gains do not settle durability or safety questions.
Myth: Laser only needs one simple decision
False. Suitability, expectations, alternatives and follow-up all still matter.
Better lens
Treat laser as a developing option with some encouraging signals, not as certainty in a new wrapper.
Best next step
If laser interests you, ask for an evidence-based explanation of what is known, what is unknown and what first-line options remain relevant.
When self-care may be enough and when to get checked
These signs help separate sensible self-care from symptoms that deserve a proper medical review.
Mild pattern
Symptoms are mild, clearly linked to judging symptom improvement claims for vaginal laser against the current limits of the evidence base and start improving with the right moisturiser, lubricant or trigger avoidance.
No red-flag bleeding
There is no bleeding after sex, no bleeding after menopause and no new abnormal discharge.
Daily life still manageable
Comfort, intimacy and bladder symptoms remain manageable while you try evidence-based self-care.
Clear follow-up plan
You know when to escalate if symptoms persist, worsen or start to affect intimacy, sleep or confidence.
Reassuring Signs Matrix (Green Flags)
Reasonable first steps at home usually include:
Indicators to Pause and Re-Evaluate (Red Flags)
Get a clinical review sooner if you notice:
Signs Demanding Immediate Clinical Evaluation
Dryness is common, but it should not be brushed off if the symptom pattern changes or starts affecting pain, bleeding, bladder symptoms or quality of life. Access NHS 111 Support
Bleeding needs checking
Postmenopausal bleeding or repeated bleeding after sex should be assessed rather than assumed to be simple dryness.
Pain is not always only dryness
Pain can also reflect infection, pelvic floor spasm, vulval skin disease or another diagnosis that needs a different plan.
Urinary symptoms matter
Frequency, urgency, recurrent UTIs or bladder discomfort can sit alongside GSM and deserve review.
Persistent symptoms deserve options
If symptoms are ongoing, ask about evidence-based treatment rather than cycling through unsuitable over-the-counter products.
This safety and escalation advice is purely educational and does not replace emergency medical care. If you are experiencing severe, worsening pain, heavy active bleeding, signs of systemic infection, acute urinary retention, or sudden incontinence, please contact NHS 111, your local GP, or an urgent care centre immediately.
Deep Clinical Context & Common Patient Inquiries
What current UK guidance actually says
NICE has taken a clear position on transvaginal laser therapy for urogenital atrophy: it should only be used as part of a research study. That is the most important anchor when judging any strong effectiveness claim. It does not mean laser can never help. It means the evidence is not yet secure enough for routine unrestricted use.That distinction matters.Why some clinicians and patients are still interested
RCOG and BMS both acknowledge that studies have reported symptomatic improvement and that laser may have a role for selected women, particularly where hormonal options are unsuitable or adherence is difficult. But both also make clear that the evidence base still needs better quality, longer-term data.Promising is not the same thing as established.Questions worth asking before pursuing laser
- Have standard options been optimised first? Local oestrogen and sensible non-hormonal care remain core treatments.
- What evidence is this recommendation based on? Ask whether the explanation is drawing on guidance or mainly on marketing language.
- What is the fallback plan? Know how progress, failure and repeat treatment would be handled.
Authoritative UK Clinical Resources
Access peer-reviewed guidance from national healthcare bodies to support your understanding of pelvic health conditions.
NICE laser guidance overview
NICE summarises the procedure and keeps the current recommendation anchored to the available evidence base.Read NICE guidance
NICE patient information
This page states clearly that transvaginal laser therapy should only be done in a research study.Read NICE guidance
BMS GSM consensus statement
BMS outlines where laser may fit for selected women while still emphasising the need for better randomised evidence.Read BMS guidance
Next step
Schedule a Confidential Specialist Evaluation
If you are weighing laser for vaginal atrophy symptoms, WHC can help separate short-term promise from what current UK guidance actually supports.
Clinical reference materials used for this FAQ
- Transvaginal laser therapy for urogenital atrophy | Guidance | NICE
- Information for the public | Transvaginal laser therapy for urogenital atrophy | Guidance | NICE
- Genitourinary Syndrome of Menopause (GSM) - British Menopause Society
- Laser treatment for genitourinary syndrome of menopause (Scientific Impact Paper No. 72) | RCOG
Educational only. Individual treatment suitability can only be determined by a qualified professional after a thorough consultation and assessment. Results vary. Not a cure.
